# A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

> **NCT01730222** · PHASE1,PHASE2 · COMPLETED · sponsor: **IRCCS San Raffaele** · enrollment: 137 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** capecitabine
- **DRUG:** gemcitabine
- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT01730222
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2017-02
- **Final completion:** 2017-08
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2017-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01730222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01730222, "A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01730222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*